News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
764,318 Results
Type
Article (45975)
Company Profile (294)
Press Release (718038)
Multimedia
Podcasts (133)
Webinars (23)
Section
Business (212686)
Career Advice (2126)
Deals (36629)
Drug Delivery (142)
Drug Development (82889)
Employer Resources (177)
FDA (17120)
Job Trends (15469)
News (358110)
Policy (33657)
Tag
2027 BioCapital Elite (1)
2027 BioCapital Standard (1)
2027 BioMidwest Elite (1)
2027 Bio NC Standard (1)
2027 Biotech Bay Elite (2)
2027 Biotech Bay Standard (3)
2027 Biotech Beach Elite (1)
2027 Biotech Beach Standard (1)
2027 Genetown Elite (3)
2027 Genetown Standard (3)
2027 Pharm Country Elite (2)
2027 Pharm Country Standard (5)
Academia (2763)
Accelerated approval (55)
ADA (45)
Adcomms (29)
Allergies (200)
Alliances (52633)
ALS (230)
Alzheimer's disease (1873)
Antibody-drug conjugate (ADC) (540)
Approvals (17597)
Artificial intelligence (786)
ASCO (330)
Autoimmune disease (355)
Automation (66)
Bankruptcy (369)
Best Places to Work (11930)
BIO (72)
BIOSECURE Act (20)
Biosimilars (237)
Biotechnology (193)
Bladder cancer (207)
Brain cancer (77)
Breast cancer (816)
Cancer (6427)
Cardiovascular disease (513)
Career advice (1814)
Career pathing (46)
CAR-T (370)
CDC (60)
Celiac Disease (3)
Cell therapy (1003)
Cervical cancer (56)
Clinical research (72435)
Collaboration (2312)
Commercialization (1)
Company closure (6)
Compensation (1538)
Complete response letters (86)
COVID-19 (2842)
CRISPR (124)
C-suite (1288)
Cystic fibrosis (163)
Data (8761)
Decentralized trials (3)
Denatured (47)
Depression (177)
Dermatology (99)
Diabetes (675)
Diagnostics (7325)
Digital health (67)
Diversity (14)
Diversity, equity & inclusion (45)
Drug discovery (380)
Drug pricing (206)
Drug shortages (33)
Duchenne muscular dystrophy (314)
Earnings (93973)
Editorial (69)
Employer branding (22)
Employer resources (160)
Events (125626)
Executive appointments (1171)
FDA (21240)
Fibrodysplasia Ossificans Progressiva (10)
Friedreich's ataxia (22)
Frontotemporal dementia (35)
Funding (1927)
Gene editing (263)
Generative AI (69)
Gene therapy (789)
GLP-1 (1116)
Government (4864)
Grass and pollen (7)
Guidances (424)
Healthcare (19882)
Hematology (192)
HIV (94)
Huntington's disease (62)
IgA nephropathy (113)
Immunology and inflammation (307)
Immuno-oncology (108)
Indications (225)
Infectious disease (3218)
Inflammatory bowel disease (229)
Inflation Reduction Act (14)
Influenza (146)
Intellectual property (328)
Interviews (333)
IPO (17027)
IRA (51)
Job creations (3839)
Job search strategy (1504)
JPM (62)
Kidney cancer (21)
Labor market (113)
Layoffs (593)
Leadership (44)
Legal (8182)
Liver cancer (105)
Longevity (35)
Lung cancer (841)
Lymphoma (480)
Machine learning (68)
Management (65)
Manufacturing (1190)
Marketing (4)
MASH (211)
Medical affairs (1)
Medical device (14758)
Medtech (14940)
Mergers & acquisitions (20941)
Metabolic disorders (1671)
mRNA (256)
Multiple sclerosis (200)
NASH (17)
Neurodegenerative disease (472)
Neuropsychiatric disorders (109)
Neuroscience (3539)
Neurotech (1)
NextGen: Class of 2026 (6858)
Non-profit (4677)
Now hiring (83)
Obesity (764)
Opinion (312)
Ovarian cancer (245)
Pain (268)
Pancreatic cancer (360)
Parkinson's disease (402)
Partnered (37)
Patents (659)
Patient recruitment (790)
Peanut (70)
People (62259)
Pharmaceutical (61)
Pharmacy benefit managers (34)
Phase 1 (22749)
Phase 2 (31886)
Phase 3 (23626)
Pipeline (10028)
Policy (341)
Postmarket research (2590)
Preclinical (9754)
Press Release (71)
Prostate cancer (341)
Psychedelics (57)
Radiopharmaceuticals (370)
Rare diseases (1203)
Real estate (6305)
Recruiting (71)
Regulatory (26524)
Reports (56)
Research institute (2571)
Resumes & cover letters (366)
Rett syndrome (46)
RNA editing (28)
RSV (91)
Schizophrenia (186)
Series A (331)
Series B (241)
Service/supplier (13)
Sickle cell disease (123)
Special edition (25)
Spinal muscular atrophy (170)
Sponsored (49)
Startups (3918)
State (2)
Stomach cancer (18)
Supply chain (135)
Tariffs (87)
The Weekly (83)
Vaccines (1202)
Venture capital (127)
Weight loss (490)
Women's health (141)
Worklife (21)
Date
Last 7 days (490)
Last 30 days (2096)
Last 365 days (31085)
2026 (16793)
2025 (30953)
2024 (36171)
2023 (41133)
2022 (52398)
2021 (56990)
2020 (55611)
2019 (48405)
2018 (36442)
2017 (33539)
2016 (33144)
2015 (39363)
2014 (32946)
2013 (27994)
2012 (30251)
2011 (30854)
2010 (28815)
Location
Africa (783)
Alabama (96)
Alaska (7)
Arizona (380)
Arkansas (16)
Asia (42715)
Australia (7111)
California (14299)
Canada (4004)
China (1543)
Colorado (611)
Connecticut (628)
Delaware (447)
Europe (94150)
Florida (2136)
Georgia (463)
Hawaii (3)
Idaho (66)
Illinois (1190)
India (100)
Indiana (645)
Iowa (26)
Japan (614)
Kansas (138)
Kentucky (54)
Louisiana (60)
Maine (76)
Maryland (1692)
Massachusetts (10363)
Michigan (407)
Minnesota (781)
Mississippi (7)
Missouri (161)
Montana (36)
Nebraska (30)
Nevada (154)
New Hampshire (91)
New Jersey (3743)
New Mexico (32)
New York (3747)
North Carolina (1825)
North Dakota (11)
Northern California (7200)
Ohio (438)
Oklahoma (25)
Oregon (45)
Pennsylvania (2822)
Puerto Rico (33)
Rhode Island (53)
South America (1171)
South Carolina (88)
South Dakota (2)
Southern California (5679)
Tennessee (235)
Texas (2307)
United States (50646)
Utah (429)
Vermont (2)
Virginia (352)
Washington D.C. (82)
Washington State (1147)
West Virginia (4)
Wisconsin (147)
Wyoming (2)
764,318 Results for "retractable technologies inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Regulatory
Amgen’s Tavneos troubles continue as
NEJM
retracts pivotal publication
Earlier this year, Amgen refused the FDA’s request to withdraw Tavneos from the market. Now, two researchers who participated in the original study to support the drug’s approval claim they did not know the primary endpoint was readjudicated after the study was unblinded.
June 30, 2026
·
2 min read
·
Tristan Manalac
Press Releases
Retractable Technologies, Inc. Results for the Periods Ended June 30, 2025
August 15, 2025
·
8 min read
Lone Star Bio
Retractable Technologies, Inc. Reports Results for 2023
Retractable Technologies, Inc. reports the following information relating to the year ended December 31, 2023.
March 29, 2024
·
4 min read
Policy
Retractable Technologies, Inc. Not Impacted by FDA Safety Communication
Retractable Technologies, Inc. reports that the FDA Safety Communication “Evaluating Plastic Syringes Made in China for Potential Device Failures” on November 30, 2023 does not refer to syringes from Retractable Technologies Inc.
December 1, 2023
·
2 min read
Business
Retractable Technologies, Inc. Results for the Period Ended March 31, 2024
Retractable Technologies, Inc. (NYSE American: RVP) reports total net sales of $7.6 million for the first three months of 2024 and an operating loss of nearly $3.0 million for the period, as compared to total net sales for the same period last year of $11.0 million and an operating loss of $2.7 million.
May 15, 2024
·
5 min read
Policy
Germany rethinking drug price reforms after Lilly, Boehringer withdraw investments:
Reuters
Weeks after Boehringer Ingelheim and Eli Lilly retracted billions of dollar in German commitments, the nation’s government is reportedly changing a contentious element of its planned healthcare reforms.
June 15, 2026
·
2 min read
·
Nick Paul Taylor
Podcast
Sentiment at BIO soars as FDA resets, dealmaking evolves; Amgen’s Tavneos in hot water
The vibe at BIO 2026 in San Diego last week was overwhelmingly positive, with attendees observing noticeable changes at the FDA and an uptick in dealmaking and IPOs. Plus, a top medical journal this week retracted a pivotal study for Amgen’s rare disease drug Tavneos, which has been in the FDA’s crosshairs since January.
July 1, 2026
·
2 min read
·
Jef Akst
Press Releases
OraSure Technologies, Inc. Announces FDA Clearance that Expands Patient‑Friendly Access to Testing for Sexually Transmitted Infections
June 11, 2026
·
5 min read
Business
Retractable Technologies, Inc. Reports Results For 2022
Retractable Technologies, Inc. reports the following information relating to the year ended December 31, 2022.
March 30, 2023
·
4 min read
Lone Star Bio
Retractable Technologies, Inc. Results for the Periods Ended September 30, 2023
Retractable Technologies, Inc. reports that its loss from operations was $8.7 million for the first nine months of 2023 and that it had an operating loss of $936 thousand for the third quarter of 2023, as compared to an operating income for the same periods last year of $7.0 million for the first nine months of 2022 and an operating loss of $691 thousand for the third quarter of 2022.
November 14, 2023
·
7 min read
1 of 76,432
Next